PDF(Pubmed)
Abstract：
BACKGROUND: A new concept of HER2-low has emerged in recent years. However, the prognostic value and the relapse pattern of HER2-low is unclear.
METHODS: Our study included patients diagnosed with HER2-negative/hormone receptor-positive breast cancer to explore the differences in survival outcomes between the HER2-low group and the HER2-zero group. More importantly, we explored different recurrence patterns, including the comparison of metastatic sites and recurrence time curve between the two groups.
RESULTS: A total of 797 patients with hormone receptor-positive breast cancer were analyzed. Similar disease-free survival (DFS) was observed between the HER2-low group and HER2-zero group (HR 0.84, 95% CI: 0.61-1.16, p = 0.290). There was also no significant difference in OS between the HER2-low group and the HER2-zero group (HR 0.77, 95% CI: 0.46-1.28, p = 0.310). When IHC 1+ and 0 were taken as a group, the IHC 2+ group had significantly better DFS than the IHC 1+ and 0 group in some subgroups. The risk of bone metastasis in patients with HER2 IHC 1+ and 0 was significantly higher than that of patients with HER2 IHC 2+ (12.7% vs. 4.7%, p < 0.001). Compared with the HER2-zero group, we found that the HER2-low group had a more obvious peak in mortality at the time of postoperative 80th-100th month.
CONCLUSIONS: No significant difference in DFS and OS between the HER2-low group and the HER2-zero group was observed. Patients with HER2 IHC 1+ and 0 tend to develop bone metastasis. The HER2-low group had a more obvious second peak in mortality.
METHODS: Our study included patients diagnosed with HER2-negative/hormone receptor-positive breast cancer to explore the differences in survival outcomes between the HER2-low group and the HER2-zero group. More importantly, we explored different recurrence patterns, including the comparison of metastatic sites and recurrence time curve between the two groups.
RESULTS: A total of 797 patients with hormone receptor-positive breast cancer were analyzed. Similar disease-free survival (DFS) was observed between the HER2-low group and HER2-zero group (HR 0.84, 95% CI: 0.61-1.16, p = 0.290). There was also no significant difference in OS between the HER2-low group and the HER2-zero group (HR 0.77, 95% CI: 0.46-1.28, p = 0.310). When IHC 1+ and 0 were taken as a group, the IHC 2+ group had significantly better DFS than the IHC 1+ and 0 group in some subgroups. The risk of bone metastasis in patients with HER2 IHC 1+ and 0 was significantly higher than that of patients with HER2 IHC 2+ (12.7% vs. 4.7%, p < 0.001). Compared with the HER2-zero group, we found that the HER2-low group had a more obvious peak in mortality at the time of postoperative 80th-100th month.
CONCLUSIONS: No significant difference in DFS and OS between the HER2-low group and the HER2-zero group was observed. Patients with HER2 IHC 1+ and 0 tend to develop bone metastasis. The HER2-low group had a more obvious second peak in mortality.
摘要：
背景：近年来出现了HER2低的新概念。然而,低HER2的预后价值和复发模式尚不清楚.
方法：我们的研究纳入了被诊断为HER2阴性/激素受体阳性乳腺癌的患者，以探讨HER2低组和HER2零组之间生存结局的差异。更重要的是,我们探索了不同的复发模式，包括比较两组的转移部位和复发时间曲线。
结果：共分析了797例激素受体阳性乳腺癌患者。在HER2低组和HER2零组之间观察到相似的无病生存期（DFS）（HR0.84，95％CI：0.61-1.16，p=0.290）。HER2低组和HER2零组之间的OS也没有显着差异（HR0.77，95％CI：0.46-1.28，p=0.310）。当IHC1+和0作为一组时，在某些亚组中，IHC2+组的DFS明显优于IHC1+和0组。HER2IHC1+和0患者骨转移风险明显高于HER2IHC2+患者(12.7%vs.4.7%，p<0.001)。与HER2零组相比，我们发现低HER2组的死亡率在术后第80-100个月时有更明显的峰值.
结论：HER2低组和HER2零组的DFS和OS无显著差异。HER2IHC1+和0的患者倾向于发展骨转移。低HER2组的死亡率有一个更明显的第二高峰。
方法：我们的研究纳入了被诊断为HER2阴性/激素受体阳性乳腺癌的患者，以探讨HER2低组和HER2零组之间生存结局的差异。更重要的是,我们探索了不同的复发模式，包括比较两组的转移部位和复发时间曲线。
结果：共分析了797例激素受体阳性乳腺癌患者。在HER2低组和HER2零组之间观察到相似的无病生存期（DFS）（HR0.84，95％CI：0.61-1.16，p=0.290）。HER2低组和HER2零组之间的OS也没有显着差异（HR0.77，95％CI：0.46-1.28，p=0.310）。当IHC1+和0作为一组时，在某些亚组中，IHC2+组的DFS明显优于IHC1+和0组。HER2IHC1+和0患者骨转移风险明显高于HER2IHC2+患者(12.7%vs.4.7%，p<0.001)。与HER2零组相比，我们发现低HER2组的死亡率在术后第80-100个月时有更明显的峰值.
结论：HER2低组和HER2零组的DFS和OS无显著差异。HER2IHC1+和0的患者倾向于发展骨转移。低HER2组的死亡率有一个更明显的第二高峰。
